Apexigen (SPAC NASDAQ: APGN) is a clinical-stage biopharmaceutical company discovering and developing the next generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products that harness the patient’s immune system to combat and eradicate cancer. 

Apexigen went public in a SPAC merger with Brookline Capital Aqcuisition Corporation.

​

SPAC merger date: Q2 2022

​

​